List of Excipients in Branded Drug SAXAGLIPTIN

Generic Drugs Containing SAXAGLIPTIN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	AMMONIA
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	HYDROCHLORIC ACID
Mylan Pharmaceuticals Inc	saxagliptin	0378-4705	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in SAXAGLIPTIN?

# Of NDCs	Excipient
3	AMMONIA
1	ASCORBIC ACID
1	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

Saxagliptin Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Saxagliptin is a low-dose, immediate-release DPP-4 inhibitor with a mature U.S. product franchise. The main excipient opportunity is not discovery of a new delivery system. It is development of robust, low-cost generic tablets, fixed-dose combinations, differentiated packaging, and region-specific formulations that manage moisture, dose uniformity, and manufacturing cost.

The reference product, Onglyza, is an immediate-release film-coated tablet in 2.5 mg and 5 mg strengths. FDA-approved combination products include Kombiglyze XR with metformin extended release and Qtern with dapagliflozin. Saxagliptin is not a biologic, so biosimilar regulation does not apply. Generic competition follows the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[1]

What is saxagliptin and how does its formulation affect excipient selection?

Saxagliptin is an orally active DPP-4 inhibitor used for glycemic control in adults with type 2 diabetes. Onglyza is administered once daily, with or without food. The standard strengths are 2.5 mg and 5 mg.[2]

The low active pharmaceutical ingredient load creates a dose-uniformity challenge. A 2.5 mg tablet contains a relatively small quantity of active ingredient compared with the total tablet mass. Excipient selection therefore has a direct impact on blend uniformity, segregation, tablet weight variation, dissolution, and content uniformity.

Saxagliptin products must also accommodate renal dose adjustment. The FDA label recommends 2.5 mg once daily for patients with moderate or severe renal impairment and for patients receiving strong CYP3A4/5 inhibitors.[2] A commercially successful formulation should support both strengths without excessive manufacturing complexity.

Key pharmaceutical characteristics

Attribute	Commercial formulation relevance
Drug class	DPP-4 inhibitor
Reference brand	Onglyza
Approved strengths	2.5 mg and 5 mg
Dosage form	Immediate-release film-coated tablet
Administration	Once daily, with or without food
Dose adjustment	Required in renal impairment and with strong CYP3A4/5 inhibitors
Biologic status	Not applicable; no biosimilar pathway
Primary generic route	ANDA, subject to FDA bioequivalence requirements
Combination products	Metformin XR and dapagliflozin combinations

What excipients are used in Onglyza tablets?

Onglyza uses a conventional direct-compression or high-shear tablet platform centered on lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating system uses polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, and colorants.[2]

Reference-product excipient profile

Functional role	Onglyza excipient or excipient class	Formulation function
Diluent	Lactose monohydrate	Tablet mass and compressibility
Diluent and dry binder	Microcrystalline cellulose	Compactability and mechanical strength
Superdisintegrant	Croscarmellose sodium	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and manufacturing control
Film former	Polyvinyl alcohol	Coating integrity
Plasticizer or coating aid	Polyethylene glycol	Flexibility and processing
Opacifier	Titanium dioxide	Appearance and light protection
Anti-tacking agent	Talc	Coating-process control
Colorants	Iron oxides and related pigments	Strength identification

The commercial formulation is deliberately conventional. It does not depend on a modified-release matrix, lipid vehicle, enteric coating, osmotic system, or nanotechnology platform. That limits formulation differentiation but supports a low-cost generic development program.

What is the best excipient strategy for generic saxagliptin?

The highest-probability strategy is an immediate-release tablet that matches the reference product’s critical quality attributes rather than its complete qualitative and quantitative excipient composition.

FDA ANDA applicants generally need to establish pharmaceutical equivalence and bioequivalence. A generic product can use different inactive ingredients if the product remains pharmaceutically equivalent, meets quality requirements, and does not create safety, tolerability, or performance concerns.[1,3]

Preferred core formulation platform

A practical generic core may use:

• Microcrystalline cellulose for compactability
• Lactose or mannitol as a diluent
• Croscarmellose sodium or sodium starch glycolate as the disintegrant
• Colloidal silicon dioxide where flow improvement is needed
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Povidone or low-substituted hydroxypropyl cellulose if granulation or binding is required

The choice between lactose and mannitol is commercially important. Lactose is typically cost-efficient and compatible with conventional tablet processing, but it may be unsuitable for some lactose-intolerant or specialty-market positioning. Mannitol can improve mouthfeel and avoid lactose but usually increases raw-material cost.

Direct compression versus wet granulation

Direct compression offers the lowest process cost and the shortest manufacturing cycle. It is attractive when the active ingredient has adequate flow and the formulation can achieve content uniformity at the 2.5 mg strength.

Wet granulation may improve low-dose distribution and reduce segregation, but it adds solvent, drying, validation, and energy costs. It can also increase exposure to moisture and heat. For saxagliptin, the preferred development sequence is usually direct compression screening followed by granulation only if blend uniformity or tablet robustness fails.

Excipient controls that matter most

1. Particle-size distribution of the active ingredient and principal diluent.
2. Blend segregation during transfer and compression.
3. Lubrication time and magnesium stearate concentration.
4. Tablet disintegration after film coating.
5. Water activity and packaging performance.
6. Dissolution similarity across both strengths.
7. Content uniformity at the 2.5 mg dose.

An over-lubricated tablet can show slower dissolution and reduced compact strength. Excessive superdisintegrant can increase friability or create variable tablet structure. These are more likely failure points than the absence of a novel excipient.

What formulation patents protect saxagliptin products?

Saxagliptin’s principal commercial protection was historically tied to the active compound and related pharmaceutical claims, while combination products and extended-release metformin products had separate intellectual-property positions. The original U.S. compound protection associated with saxagliptin expired around 2020, including applicable pediatric-extension timing where relevant.[4]

Excipient-only claims are generally difficult to enforce unless the formulation has a specific technical effect and narrow claim language. A generic company should distinguish among:

• Active-compound patents
• Salt, crystalline-form, or polymorph claims
• Combination-product claims
• Method-of-use patents
• Extended-release metformin platform patents
• Manufacturing-process claims
• Packaging or stability claims

Onglyza’s immediate-release tablet does not present the same formulation barrier as a long-acting injectable or complex modified-release product. The major freedom-to-operate issue is therefore product-specific patent and regulatory review rather than a high technical barrier to reproducing the dosage form.

How many patents cover saxagliptin?

The relevant patent count depends on the product and jurisdiction. A count based only on Orange Book listings will not capture expired patents, foreign patents, pending applications, manufacturing patents, or patents covering combination products.

For a U.S. generic program, the most relevant review should cover:

Review area	Relevance to saxagliptin
Onglyza Orange Book listings	Immediate-release saxagliptin tablets
Kombiglyze XR listings	Saxagliptin/metformin extended release
Qtern listings	Saxagliptin/dapagliflozin combination
FDA exclusivity records	Regulatory timing rather than formulation freedom to operate
Patent Cooperation Treaty filings	Foreign prosecution and regional rights
Process patents	API and intermediate manufacturing risk
Crystalline-form patents	Solid-state control and supply-chain restrictions

Because saxagliptin is a small molecule, biosimilar risk is absent. The competitive threat is conventional generic entry, fixed-dose substitution, and price erosion.

When did saxagliptin lose exclusivity?

U.S. regulatory exclusivity for the original Onglyza approval was separate from patent protection. Onglyza received FDA approval in July 2009.[5] The product’s commercial protection then depended on listed patents, pediatric exclusivity, and the timing of ANDA challenges.

The original saxagliptin compound patent protection reached its effective end around 2020. Since then, the economic question has shifted from patent validity to generic launch timing, manufacturing scale, distribution access, and payer formulary treatment.

Milestone	Date or status
Onglyza FDA approval	July 31, 2009
Kombiglyze XR approval	2010
Qtern approval	2017
Core saxagliptin U.S. patent protection	Expired around 2020, subject to applicable extensions
Current competitive issue	Generic and combination-product price pressure

What is the FDA regulatory status of saxagliptin?

Saxagliptin remains an FDA-approved small-molecule drug. The reference product is Onglyza, marketed by AstraZeneca after the company acquired the diabetes business associated with Bristol-Myers Squibb.[2,6]

The FDA label includes warnings concerning heart failure risk. The label reports that patients treated with Onglyza had a higher rate of hospitalization for heart failure in a cardiovascular-outcomes trial, particularly among patients with a history of heart failure or renal impairment.[2] This warning affects commercial positioning and may influence payer and prescriber preference relative to other DPP-4 inhibitors.

Saxagliptin also has clinically relevant CYP3A4/5 interactions. Strong inhibitors require dose reduction to 2.5 mg once daily.[2] This creates a practical reason to preserve a reliable 2.5 mg product rather than focus only on the 5 mg strength.

What commercial opportunities exist for saxagliptin excipients?

Low-cost generic Onglyza tablets

The clearest opportunity is a robust, low-cost tablet platform using widely available compendial excipients. The formulation should minimize:

• Specialized excipient sourcing
• Granulation steps
• Coating complexity
• High-cost analytical methods
• Packaging requirements beyond demonstrated stability needs

A generic developer can compete through manufacturing yield, reliable low-dose content uniformity, and supply continuity rather than through a novel clinical claim.

Fixed-dose combinations

Saxagliptin has commercial relevance in combination products:

• Saxagliptin plus metformin XR
• Saxagliptin plus dapagliflozin
• Potential regional combinations with other antihyperglycemic agents, subject to regulatory strategy

Combination products create greater excipient complexity. Metformin XR requires a controlled-release matrix, while dapagliflozin adds a second active ingredient with its own stability and dissolution requirements. A formulation developer can create value through reduced tablet count, improved robustness, and common manufacturing equipment.

Excipient substitution for supply resilience

Lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate are broadly available. Even so, dual sourcing can reduce disruption risk. Substitution programs may evaluate:

• Mannitol for lactose
• Sodium stearyl fumarate for magnesium stearate
• Crospovidone or sodium starch glycolate for croscarmellose sodium
• Spray-dried lactose or silicified microcrystalline cellulose for improved flow

Each substitution requires assessment of blend uniformity, dissolution, impurity formation, tablet strength, and stability. Excipient substitution is commercially valuable when it removes dependence on a single supplier, but it rarely creates durable market exclusivity.

Patient-friendly dosage forms

Orally disintegrating tablets, mini-tablets, and sprinkle formulations could address swallowing difficulty or adherence. Their commercial value is less certain because saxagliptin is already once daily and available in a small conventional tablet.

An orally disintegrating product would require control of taste, moisture sensitivity, friability, mouthfeel, and packaging. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems could be considered. The product would need a clear market-access advantage to justify development and registration costs.

Emerging-market presentations

In price-sensitive markets, the opportunity is usually a simple blister-packed immediate-release tablet. Commercial priorities include:

• Heat and humidity stability
• Aluminum-aluminum blister protection where justified
• Low-cost film coating
• Clearly differentiated 2.5 mg and 5 mg color coding
• Flexible pack sizes
• Regional regulatory acceptability of excipients

A bottle may reduce packaging cost but can increase moisture exposure and dose-removal variability. Blister selection should follow stability data rather than a universal packaging assumption.

How does saxagliptin compare with competing DPP-4 inhibitors?

Product	Active ingredient	Typical formulation	Main excipient opportunity	Commercial constraint
Onglyza	Saxagliptin	Immediate-release tablet	Low-cost generic and combination tablet	Heart-failure warning and mature market
Januvia	Sitagliptin	Immediate-release tablet	Generic scale and fixed-dose combinations	Strong incumbent brand and broad use
Tradjenta	Linagliptin	Immediate-release tablet	Generic tablet and renal-dose simplicity	Established DPP-4 competition
Nesina	Alogliptin	Immediate-release tablet	Cost-focused generic supply	Smaller commercial base
Kombiglyze XR	Saxagliptin/metformin	Extended-release combination	Matrix robustness and tablet-size reduction	More complex dissolution and manufacturing
Qtern	Saxagliptin/dapagliflozin	Immediate-release combination	Co-formulation and adherence positioning	Competition from other SGLT2/DPP-4 combinations

Saxagliptin has a formulation advantage in its simplicity but a commercial disadvantage in market maturity and cardiovascular labeling. Linagliptin has a renal-dosing advantage, while sitagliptin has broader market recognition. Saxagliptin’s most defensible opportunity is operational efficiency in generic and combination manufacturing.

What patent litigation and Paragraph IV risks affect saxagliptin?

Paragraph IV risk is most relevant when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For the original saxagliptin product, the principal compound protection has expired, reducing the importance of new Paragraph IV litigation around the basic immediate-release tablet.

Risk remains product-specific for:

• Kombiglyze XR extended-release technology
• Qtern combination claims
• Manufacturing processes
• Crystalline forms
• New methods of use
• Foreign-market patents with later expiration dates

A generic entrant should assess whether a planned product is an ANDA for saxagliptin alone or a separate combination-product application. The regulatory and litigation profile differs materially between the two.

What generic launch scenarios exist for saxagliptin?

Scenario 1: Standard immediate-release generic

This is the lowest-risk development path. A developer uses a conventional tablet, demonstrates bioequivalence, and competes primarily on price and supply reliability.

Scenario 2: Differentiated excipient platform

A developer substitutes lactose-free or moisture-tolerant excipients. The product may gain procurement or regional-market value, but the formulation is unlikely to command a large premium without a documented clinical or adherence benefit.

Scenario 3: Combination-product launch

A saxagliptin/metformin or saxagliptin/dapagliflozin product can reduce pill burden. It requires more complex formulation development, analytical validation, and regulatory strategy.

Scenario 4: Patient-friendly dosage form

An orally disintegrating or sprinkle formulation may target adherence or swallowing limitations. This path has higher formulation and packaging risk and requires a focused commercial rationale.

How strong is the saxagliptin formulation estate?

The formulation estate for conventional saxagliptin tablets is moderate to weak from a barrier-to-entry perspective. The dosage form uses standard excipients and does not require sophisticated delivery technology.

The stronger intellectual-property positions are more likely to arise in:

• Combination products
• Extended-release systems
• Specific crystalline forms
• Manufacturing methods
• New clinical uses
• Stability-enhancing compositions with narrow claims

An excipient strategy can improve cost, quality, and supply security. It should not be treated as a substitute for a patent strategy unless the formulation produces a measurable technical effect that supports enforceable claims.

Key Takeaways

• Saxagliptin is a mature small-molecule DPP-4 inhibitor with no biosimilar pathway.
• Onglyza uses a conventional immediate-release tablet containing lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
• The main technical challenge is low-dose content uniformity, especially for the 2.5 mg strength.
• Direct compression is the preferred first-line generic manufacturing platform; wet granulation is a fallback for flow or uniformity problems.
• Commercial value is concentrated in low-cost generics, fixed-dose combinations, supply resilience, and selected patient-friendly presentations.
• The original U.S. saxagliptin compound protection expired around 2020, shifting competition toward manufacturing economics and market access.
• Combination products, extended-release metformin technology, and process patents require separate freedom-to-operate analysis.
• Excipient changes can improve cost and stability but generally provide limited standalone exclusivity.

FAQs

Can saxagliptin be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking agents. The commercial case depends on demonstrated adherence or swallowing benefits.

Which excipient is most important for saxagliptin dose uniformity?

The diluent and blending system are the most important variables because the 2.5 mg dose creates a low-dose uniformity challenge. Particle-size matching and segregation control are usually more important than selecting a novel superdisintegrant.

Does saxagliptin require a lipid-based formulation?

No. The approved Onglyza tablet is a conventional immediate-release solid oral dosage form. A lipid-based system would add cost and complexity without an established commercial requirement.

Are saxagliptin excipient patents likely to block generic entry?

Broad excipient patents are unlikely to block a conventional generic tablet. Risk is higher for narrow claims involving combination products, extended release, crystalline forms, manufacturing processes, or demonstrated stability improvements.

Is saxagliptin still commercially attractive after patent expiry?

It can be attractive for manufacturers with efficient tablet production, regional distribution, or combination-product capability. The opportunity is strongest where reliable supply and low cost matter more than premium brand differentiation.

References

1. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of abbreviated new drug applications. FDA.

2. U.S. Food and Drug Administration. (2023). Onglyza (saxagliptin) prescribing information. AstraZeneca Pharmaceuticals LP.

3. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly variable drugs. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2009). FDA approves Onglyza to treat type 2 diabetes. FDA.

6. AstraZeneca PLC. (2014). Annual report and Form 20-F 2014. AstraZeneca.